Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PT Jayamas Medica Industri Tbk's annualized ROCE % for the quarter that ended in Jun. 2026 was 20.44%.
PT Jayamas Medica Industri Tbk (ISX:OMED) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
PT Jayamas Medica Industri Tbk ROCE % Related Terms
PT Jayamas Medica Industri Tbk ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk (ISX:OMED) has a ROCE % of 20.44% as of Jun. 2026.
Is PT Jayamas Medica Industri Tbk's ROCE % too high?
PT Jayamas Medica Industri Tbk's current ROCE % is 20.44%. The Medical Devices & Instruments industry median ROCE % is 2.65. PT Jayamas Medica Industri Tbk's value of 20.44% is 671.3% above this industry median. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's ROCE % compare to ISRG and BDX?
PT Jayamas Medica Industri Tbk's ROCE % of 20.44% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.65. PT Jayamas Medica Industri Tbk's value of 20.44% is 671.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.65, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Jayamas Medica Industri Tbk's current ROCE % of 20.44% is 671.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Jayamas Medica Industri Tbk's current ROCE % is 20.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp239.79, compared to a current price of Rp226.00 — trading 5.8% below its estimated fair value. The current ROCE % is 20.44% and 671.3% above the Medical Devices & Instruments industry median of 2.65. PT Jayamas Medica Industri Tbk's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current ROCE % is 20.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp226.00 is trading 5.8% below its estimated GF Value™ of Rp239.79.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
ROCE %: 20.44%
GF Value™: Rp239.79 vs. price of Rp226.00 (5.8% below fair value)
Industry Position: 671.3% above the Medical Devices & Instruments median
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
89GF Score
Get the complete analysis for ISX:OMED
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
